Skip to main content
SpringerLink
Log in

Substrate Reduction Therapy

  • Chapter
Lysosomal Storage Disorders

The glycosphingolipidoses are a family of storage diseases that arise due to incomplete catabolism of glycosphingolipids (GSLs) in the lysosome (Wraith, 2002). The majority are autosomal recessive disorders and result from mutations in the genes that encode the catabolic enzymes of the lysosome (Winchester, 2004). Clinically they are highly variable (Beck, 2001) but typically have a neurodegenerative course and commonly present in infancy or early childhood (Wraith, 2004). Adult-onset variants also occur (Rapola, 1994; Wraith, 2004). The age of onset is influenced by the residual enzyme activity present, that in turn reflects the impact a specific mutation has on the properties of the enzyme (Rapola, 1994; Winchester, 2004). Little or no activity leads to rapid storage and early onset of symptoms whereas higher levels of residual activity lead to a slower rate of storage and a longer presymptomatic period. In this chapter, we focus on a drug-based therapy that is relevant to all lysosomal diseases involving the storage of glucosylceramidederived GSLs, including Gaucher, Fabry, Tay-Sachs, Sandhoff, and GM1 gangliosidosis. In addition, storage diseases involving the secondary storage of GSLs

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aerts, J. M., & Hollak, C. E. (1997). Plasma and metabolic abnormalities in Gaucher’s disease. Baillieres Clin Haematol, 10(4), 691-709.

    Article  CAS  PubMed  Google Scholar 

  • Andersson, U., Butters, T. D., Dwek, R. A., & Platt, F. M. (2000). N-butyldeoxygalac-tonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol, 59(7), 821-829.

    Article  CAS  PubMed  Google Scholar 

  • Andersson, U., Reinkensmeier, G., Butters, T. D., Dwek, R. A., & Platt, F. M. (2004). Inhibition of glycogen breakdown by imino sugars in vitro and in vivo. Biochem Pharmacol, 67(4), 697-705.

    Article  CAS  PubMed  Google Scholar 

  • Andersson, U., Smith, D., Jeyakumar, M., Butters, T. D., Borja, M. C., Dwek, R. A., et al. (2004). Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol Dis, 16(3), 506-515.

    Article  CAS  PubMed  Google Scholar 

  • Beck, M. (2001). Variable clinical presentation in lysosomal storage disorders. J Inherit Metab Dis, 24 Suppl 2, 47-51; discussion 45-46.

    Article  PubMed  Google Scholar 

  • Beutler, E., & Grabowski, G. (2001). Gaucher disease. In C. R. Scriver, A. L. Beadet, D. Valle & W. S. Sly (Eds.), The metabolic and molecular bases of inherited diseases (8 ed., Vol. 3, pp. 3636-3668). New York: McGraw Hill.

    Google Scholar 

  • Block, T. M., Lu, X. Y., Mehta, A. S., Blumberg, B. S., Tennant, B., Ebling, M., et al. (1998). Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nature Med, 4(5), 610-614.

    Article  CAS  PubMed  Google Scholar 

  • Brady, R. O. (2003). Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies. Acta Paediatr Suppl, 92(443), 19-24.

    CAS  PubMed  Google Scholar 

  • Butters, T. D., Dwek, R. A., & Platt, F. M. (2000). Inhibition of Glycosphingolipid Bio-synthesis: Application to Lysosomal Storage Disorders. Chem Rev, 100, 4683-4696.

    Article  CAS  PubMed  Google Scholar 

  • Butters, T. D., Dwek, R. A., & Platt, F. M. (2003). Therapeutic applications of imino sugars in lysosomal storage disorders. Curr Top Med Chem, 3(5), 561-574.

    Article  CAS  PubMed  Google Scholar 

  • Butters, T. D., Mellor, H. R., Narita, K., Dwek, R. A., & Platt, F. M. (2003). Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos Trans R Soc Lond B Biol Sci, 358(1433), 927-945.

    Article  CAS  PubMed  Google Scholar 

  • Butters, T. D., van den Broek, L. A. G. M., Fleet, G. W. J., Krulle, T. M., Wormald, M. R., Dwek, R. A., et al. (2000). Molecular requirements of imino sugars for the selective  control of N-linked glycosylation and glycospingolipid biosynthesis. Tetrahedron Assymetry, 11, 113-124.

    Article  CAS  Google Scholar 

  • Cabrera-Salazar, M. A., Novelli, E., & Barranger, J. A. (2002). Gene therapy for the lysosomal storage disorders. Curr Opin Mol Ther, 4(4), 349-358.

    CAS  PubMed  Google Scholar 

  • Carstea, E. D., Morris, J. A., Coleman, K. G., Loftus, S. K., Zhang, D., Cummings, C., et al. (1997). Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeo-stasis. Science, 277(5323), 228-231.

    Article  CAS  PubMed  Google Scholar 

  • Cox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebicek, M., et al. (2000). Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet, 355(9214), 1481-1485.

    Article  CAS  PubMed  Google Scholar 

  • Cox, T. M., Aerts, J. M., Andria, G., Beck, M., Belmatoug, N., Bembi, B., et al. (2003). The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis, 26(6), 513-526.

    Article  CAS  PubMed  Google Scholar 

  • Dobrenis, K. (2004). Cell-mediated delivery systems. In F. M. Platt & S. U. Walkley (Eds.), Lysosomal Disorders of the Brain (pp. 339-380). Oxford: Oxford University Press.

    Chapter  Google Scholar 

  • Durantel, D., Branza-Nichita, N., Carrouee-Durantel, S., Butters, T. D., Dwek, R. A., & Zitzmann, N. (2001). Study of the Mechanism of Antiviral Action of Iminosugar Derivatives against Bovine Viral Diarrhea Virus. J Virol, 75(19), 8987-8998.

    Article  CAS  PubMed  Google Scholar 

  • Dwek, R. A., Butters, T. D., Platt, F. M., & Zitzmann, N. (2002). Targetting glycosyla-tion as a therapeutic approach. Nature drug discovery, 1(1), 65-75.

    Article  CAS  Google Scholar 

  • Elstein, D., Hollak, C., Aerts, J. M., Van Weely, S., Maas, M., Cox, T. M., et al. (2004). Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT-918) in type 1 Gaucher disease. J Inherit Metab Dis, In Press.

    Google Scholar 

  • Fischer, P. B., Collin, M., Karlsson, G. B., James, W., Butters, T. D., Davis, S. J., et al. (1995). The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J Virol, 69(9), 5791-5797.

    CAS  PubMed  Google Scholar 

  • Ginzburg, L., Kacher, Y., & Futerman, A. H. (2004). The pathogenesis of glycosphingo-lipid storage disorders. Semin Cell Dev Biol, 15(4), 417-431.

    Article  CAS  PubMed  Google Scholar 

  • Heitner, R., Elstein, D., Aerts, J., Weely, S., & Zimran, A. (2002). Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis, 28(2), 127-133.

    Article  PubMed  Google Scholar 

  • Hopwood, J. J., Crawley, A. C., & Taylor, R. M. (2004). Spontaneous and engineered mammalian storage disease models. In F. M. Platt & S. U. Walkley (Eds.), Lysosomal disorders of the brain (Vol. 1, pp. 257-289). Oxford: Oxford University Press.

    Chapter  Google Scholar 

  • Ikonen, E., & Holtta-Vuori, M. (2004). Cellular pathology of Niemann-Pick type C disease. Semin Cell Dev Biol, 15(4), 445-454.

    Article  CAS  PubMed  Google Scholar 

  • Jeyakumar, M., Butters, T. D., Cortina-Borja, M., Hunnam, V., Proia, R. L., Perry, V. H., et al. (1999). Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A, 96(11), 6388-6393.

    Article  CAS  PubMed  Google Scholar 

  • Jeyakumar, M., Smith, D. A., Williams, I. M., Borja, M. C., Neville, D. C., Butters, T. D., et al. (2004). NSAIDs increase survival in the Sandhoff disease mouse: Synergy with N-butyldeoxynojirimycin. Ann Neurol, 56(5), 642-649.

    Article  CAS  PubMed  Google Scholar 

  • Jeyakumar, M., Thomas, R., Elliot-Smith, E., Smith, D. A., van der Spoel, A. C., d’Azzo, A., et al. (2003). Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain, 126(Pt 4), 974-987.

    Article  CAS  PubMed  Google Scholar 

  • Ko, D. C., Binkley, J., Sidow, A., & Scott, M. P. (2003). The integrity of a cholesterol-binding pocket in Niemann-Pick C2 protein is necessary to control lysosome cholesterol levels. Proc Natl Acad Sci U S A, 100(5), 2518-2525.

    Article  CAS  PubMed  Google Scholar 

  • Krivit, W. (2002). Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr, 49, 359-378.

    PubMed  Google Scholar 

  • Krivit, W., Sung, J. H., Shapiro, E. G., & Lockman, L. A. (1995). Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell-Transplant, 4 (4), 385-392.

    Article  CAS  PubMed  Google Scholar 

  • Lachmann, R. H. (2003). Miglustat. Oxford GlycoSciences/Actelion. Curr Opin Investig Drugs, 4(4), 472-479.

    CAS  PubMed  Google Scholar 

  • Lachmann, R. H., & Platt, F. M. (2001). Substrate reduction therapy for glycos-phingolipid storage disorders. Exp. Opin. Invest. Drugs, 10, 455-466.

    Article  CAS  Google Scholar 

  • Lachmann, R. H., te Vruchte, D., Lloyd-Evans, E., Reinkensmeier, G., Sillence, D. J., Fernandez-Guillen, L., et al. (2004). Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis, 16(3), 654-658.

    Article  CAS  PubMed  Google Scholar 

  • Liscum, L. (2000). Niemann-Pick type C mutations cause lipid traffic jam. Traffic, 1(3), 218-225.

    Article  CAS  PubMed  Google Scholar 

  • Mayran, N., Parton, R. G., & Gruenberg, J. (2003). Annexin II regulates multivesicular endosome biogenesis in the degradation pathway of animal cells. Embo J, 22(13), 3242-3253.

    Article  CAS  PubMed  Google Scholar 

  • Mellor, H. R., Neville, D. C., Harvey, D. J., Platt, F. M., Dwek, R. A., & Butters, T. D. (2004). Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis. Biochem J, 381(Pt 3), 861-866.

    CAS  PubMed  Google Scholar 

  • Mellor, H. R., Nolan, J., Pickering, L., Wormald, M. R., Platt, F. M., Dwek, R. A., et al. (2002). Preparation, biochemical characterization and biological properties of radio-labelled N-alkylated deoxynojirimycins. Biochem J, 366(Pt 1), 225-233.

    CAS  PubMed  Google Scholar 

  • Mellor, H. R., Platt, F. M., Dwek, R. A., & Butters, T. D. (2003). Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation. Biochem J, 374(Pt 2), 307-314.

    Article  CAS  PubMed  Google Scholar 

  • Moyses, C. (2003). Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci, 358(1433), 955-960.

    Article  CAS  PubMed  Google Scholar 

  • Neufeld, E. F. (2004). Enzyme replacement therapy. In F. M. Platt & S. U. Walkley (Eds.), Lysosomal disorders of the brain (pp. 327-338). Oxford: Oxford University Press.

    Chapter  Google Scholar 

  • Ohgami, N., Ko, D. C., Thomas, M., Scott, M. P., Chang, C. C., & Chang, T. Y. (2004). Binding between the Niemann-Pick C1 protein and a photoactivatable cholesterol analog requires a functional sterol-sensing domain. Proc Natl Acad Sci U S A, 101 (34), 12473-12478.

    Article  CAS  PubMed  Google Scholar 

  • Pastores, G. M., Barnett, N. L., Bathan, P., & Kolodny, E. H. (2003). A neurological symptom survey of patients with type I Gaucher disease. J Inherit Metab Dis, 26(7), 641-645.

    Article  CAS  PubMed  Google Scholar 

  • Patterson, M. C., Vecchio, D., Prady, H., Abel, L., Ait-Alissa, N., & Wraith, J. E. (2006). Oral miglustat in Niemann-Pick type C (NPC) disease. Rev Neurol (separata) 43, 8.

    Google Scholar 

  • Platt, F. M., & Butters, T. D. (2004). Inhibition of substrate synthesis: a pharmacological approach for glycosphingolipid storage disease therapy. In F. M. Platt & S. U. Walkley (Eds.), Lysosomal Disorders of the Brain (pp. 381-408). Oxford: Oxford University Press.

    Chapter  Google Scholar 

  • Platt, F. M., Jeyakumar, M., Andersson, U., Heare, T., Dwek, R. A., & Butters, T. D. (2003). Substrate reduction therapy in mouse models of the glycosphingolipidoses. Phil. Trans. R. Soc. Lond. B, 358, 947-954.

    Article  CAS  Google Scholar 

  • Platt, F. M., Neises, G. R., Dwek, R. A., & Butters, T. D. (1994). N-butyldeoxy-nojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem, 269(11), 8362-8365.

    CAS  PubMed  Google Scholar 

  • Platt, F. M., Neises, G. R., Karlsson, G. B., Dwek, R. A., & Butters, T. D. (1994a). N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem, 269(43), 27108-27114.

    CAS  Google Scholar 

  • Platt, F. M., Neises, G. R., Reinkensmeier, G., Townsend, M. J., Perry, V. H., Proia, R. L., et al. (1997). Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science, 276(5311), 428-431.

    Article  CAS  PubMed  Google Scholar 

  • Puri, V., Watanabe, R., Dominguez, M., Sun, X., Wheatley, C. L., Marks, D. L., et al. (1999). Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat Cell Biol, 1(6), 386-388.

    Article  CAS  PubMed  Google Scholar 

  • Radin, N. S. (1996). Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J, 13(2), 153-157.

    Article  CAS  PubMed  Google Scholar 

  • Rapola, J. (1994). Lysosomal storage diseases in adults. Pathol Res Pract, 190(8), 759-766.

    CAS  PubMed  Google Scholar 

  • Ringden, O., Groth, C. G., Erikson, A., Granqvist, S., Mansson, J. E., & Sparrelid, E. (1995). Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation, 59(6), 864-870.

    CAS  PubMed  Google Scholar 

  • Sands, M. S. (2004). Gene therapy. In F. M. Platt & S. U. Walkley (Eds.), Lysosomal Disorders of the Brain (pp. 409-430). Oxford: Oxford University Press.

    Chapter  Google Scholar 

  • Sango, K., Yamanaka, S., Hoffmann, A., Okuda, Y., Grinberg, A., Westphal, H., et al. (1995). Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic pheno-type and ganglioside metabolism. Nat Genet, 11(2), 170-176.

    Article  CAS  PubMed  Google Scholar 

  • Sleat, D. E., Wiseman, J. A., El-Banna, M., Price, S. M., Verot, L., Shen, M. M., et al. (2004). Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc Natl Acad Sci U S A, 101(16), 5886-5891.

    Article  CAS  PubMed  Google Scholar 

  • Snyder, E. Y., Daley, G. Q., & Goodell, M. (2004). Taking stock and planning for the next decade: realistic prospects for stem cell therapies for the nervous system. J Neurosci Res, 76(2), 157-168.

    Article  CAS  PubMed  Google Scholar 

  • te Vruchte, D., Lloyd-Evans, E., Veldman, R. J., Neville, D. C., Dwek, R. A., Platt, F. M., et al. (2004). Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. J Biol Chem, 279(25), 26167-26175.

    Article  CAS  PubMed  Google Scholar 

  • van der Spoel, A. C., Jeyakumar, M., Butters, T. D., Charleton, H. M., Moore, H. D., Dwek, R. A., et al. (2002). Reversible infertility in male mice following oral admini-stration of alkylated imino sugars: a non-hormonal approach to male contraception. Proc. Natl. Acad. Sci. U.S.A., In Press.

    Google Scholar 

  • Vanier, M. T., & Millat, G. (2003). Niemann-Pick disease type C. Clin Genet, 64(4), 269-281.

    Article  CAS  PubMed  Google Scholar 

  • Vunnam, R. R., & Radin, N. S. (1980). Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem-Phys-Lipids, 26(3), 265-278 issn: 0009-3084.

    Article  CAS  PubMed  Google Scholar 

  • Wada, R., Tifft, C. J., & Proia, R. L. (2000). Microglial activation precedes acute neurodegeneration in Sandhoff disease and is supressed by bone marrow transplant-tation. Proc Natl Acad Sci USA, 97(20), 10954-10959.

    Article  CAS  PubMed  Google Scholar 

  • Walkley, S. U. (2004). Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol, 15(4), 433-444.

    Article  CAS  PubMed  Google Scholar 

  • Winchester, B. (2004). Primary defects in lysosomal enzymes. In F. M. Platt & S. U. Walkley (Eds.), Lysosomal Disorders of the Brain (pp. 81-130). Oxford: Oxford University Press.

    Chapter  Google Scholar 

  • Wraith, J. E. (2002). Lysosomal disorders. Semin Neonatol, 7(1), 75-83.

    Article  CAS  PubMed  Google Scholar 

  • Wraith, J. E. (2004). Clinical aspects and diagnosis. In F. M. Platt & S. U. Walkley (Eds.), Lysosomal disorders of the brain (pp. 50-77). Oxford: Oxford University Press.

    Chapter  Google Scholar 

  • Wu, Y. P., & Proia, R. L. (2004). Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc Natl Acad Sci U S A, 101 (22), 8425-8430.

    Article  CAS  PubMed  Google Scholar 

  • Yamanaka, S., Johnson, M. D., Grinberg, A., Westphal, H., Crawley, J. N., Taniike, M., et al. (1994). Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc Natl Acad Sci USA, 91(21), 9975-9979.

    Article  CAS  PubMed  Google Scholar 

  • Zervas, M., Somers, K. L., Thrall, M. A., & Walkley, S. U. (2001). Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol, 11(16), 1283-1287.

    Article  CAS  PubMed  Google Scholar 

  • Zimran, A., & Elstein, D. (2003). Gaucher disease and the clinical experience with substrate reduction therapy. Philos Trans R Soc Lond B Biol Sci, 358(1433), 961-966.

    Article  CAS  PubMed  Google Scholar 

  • Zitzmann, N., Mehta, A. S., Carrouee, S., Butters, T. D., Platt, F. M., McCauley, J., et al. (1999). Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A, 96(21), 11878-11882.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Glycobiology Institute, University of Oxford, OX1 3QU, Oxford, UK

    Frances M. Platt & Terry D. Butters

Authors
  1. Frances M. Platt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terry D. Butters
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Platt, F.M., Butters, T.D. (2007). Substrate Reduction Therapy. In: Lysosomal Storage Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-70909-3_11

Download citation

Publish with us

Policies and ethics

Search

Navigation